Walgreens fights 'staggering' $642 mln arbitration award to Humana
Pharmacy chain raises conflict question about Humana's law firm
Humana seeks confirmation of award, in dispute over drug price reimbursement
By Mike Scarcella
May 22 (Reuters) -National retail pharmacy giant Walgreen Co has asked a U.S. judge to vacate an arbitrator's award of more than $642 million to Humana Health Plan Inc in a drug-pricing dispute, calling the "staggering" sum the result of a "miscarriage of justice."
Lawyers for Walgreens made their legal challenge in a filing on Friday in Washington, D.C., federal court, in a clash over prescription drug reimbursement contracts between Walgreens and Humana.
Separately, Humana HUM.N asked the U.S. court to confirm the award.The insurer said Walgreens had submitted "millions of falsely-inflated" prescription drug prices for more than a decade, resulting in significant overcharges for Humana.
Deerfield, Illinois-based Walgreens, a subsidiary of Walgreens Boots Alliance WBA.O, argued in its filing that the arbitrator who issued the award in March "rewrote" its contracts with Humana. It also accused the arbitrator, from the JAMS arbitration forum, of using a flawed model to assess alleged damages.
In addition, Walgreens claimed that law firm Crowell & Moring should not have been allowed to represent Humana after previously advising Walgreens years earlier on drug pricingmatters at the heart of Humana's 2019 arbitration.
"The result was that the arbitrator awarded a massive windfall to Humana," Walgreens' attorneys at Reed Smith said in the court filing.
A spokesperson for Louisville, Kentucky-based Humana on Monday did not immediately respond to a message seeking comment.
A Walgreens spokesperson had no immediate comment.
Walgreens' retail pharmacy recorded $27.6 billion in revenue in the second quarter.
Walgreens separately sued Crowell in 2021 in District of Columbia Superior Court seeking, among other things, indemnification from any arbitral award, an injunction against Crowell and disgorgement of the firm's profits from its work for Humana.
A judge denied Walgreens' early effort to bar Crowell from representing Humana. Walgreens' appeal is pending.
Washington, D.C.-based Crowell has denied any conflict of interest in representing Humana against the law firm's former client Walgreens.
A spokesperson for Crowell on Monday in a statement called Walgreens' ethics claim "meritless" and said the firm was "confident that the arbitrator's thorough and well-reasoned award will be affirmed."
Walgreens in its petition to vacate Humana's award said it had long reported its retail prices as "usual and customary" on reimbursement claims. Walgreens alleged Humana was aware that the pharmacy chain's discount drug-price program was not part of "usual and customary" submissions.
The arbitrator, Elliot Gordon, on Monday did not immediately respond to a message seeking comment.
The case is Walgreen Co v. Humana Health Plan Inc, U.S. District Court, District of Columbia, No. 1:22-cv-00307-ACR.
For Walgreens: Frederick Robinson and Selina Coleman of Reed Smith
For Humana: Keith Harrison and Aryeh Portnoy of Crowell & Moring
Read more:
Walgreens appeals to keep counsel DQ fight out of arbitration
Walgreens lawsuit against Crowell & Moring clears early hurdle
Reporting by Mike Scarcella
Activos relacionados
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.
